Skip to main content

Table 1 Dose schedule for both study groups

From: Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

GROUP I

   

Escalation Level

Study Time

Dose and route of administration

Duration

Level 1 Total dose: 1 × 106 pfu

Day 1

5 × 105 pfu, intratumoral (via catheter)

15 minutes

 

Day 10

5 × 105 pfu, intracerebal (direct injection at multiple locations of resection wall)

15-30 minutes

Level 2 Total dose: 5 × 107 pfu

Day 1

2.5 × 107 pfu, intratumoral (via catheter)

15 minutes

 

Day 10

2.5 × 107 pfu, intracerebal (direct injection at multiple locations of resection wall)

15-30 minutes

Level 3 Total dose: 1 × 109 pfu

Day 1

5 × 108 pfu, intratumoral (via catheter)

15 minutes

 

Day 10

5 × 108 pfu, intracerebral (direct injection at multiple locations of resection wall)

15-30 minutes

GROUP II

   

Escalation Level

Study Time

Dose and Route of Administration

Duration

Level 1 Total dose: 1 × 106 pfu

Day 1 - 5

1 × 105 pfu, intravenous infusion

2 hours

 

Day 10

5 × 105 pfu, intracerebral (direct injection at multiple locations of resection wall)

15-30 minutes

Level 2 Total dose: 5 × 107

Day 1 - 5

0.5 × 107 pfu, intravenous infusion

2 hours

 

Day 10

2.5 × 107 pfu, intracerebral (direct injection at multiple locations of resection wall)

15-30 minutes

Level 3 Total dose: 1 × 109 pfu

Day 1 - 5

1 × 108 pfu, intravenous infusion

2 hours

 

Day 10

5 × 108 pfu, intracerebral (direct injection at multiple locations of resection wall)

15-30 minutes

  1. Specification of virus application and dose escalation during the Parvoryx01 trial: dose group 2 will be treated after completion of group 1 and after interim analysis of safety and tolerability in group 1.